Cargando...
Melanoma driver mutations and immune therapy
Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss...
Guardado en:
| Publicado en: | Oncoimmunology |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4910708/ https://ncbi.nlm.nih.gov/pubmed/27467925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1051299 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|